Phase I Clinical Trials Program, 1515 N Campbell Avenue. Tucson, AZ 85724
Hani M. Babiker, MD, is an Assistant Professor of Medicine and the Associate Director of the Phase I Program at the University of Arizona Cancer Center and a Clinical Assistant Professor in the Clinical Translational Research Division at TGen. He is board-certified in Medical Oncology, Hematology, Internal Medicine, and Geriatrics and Gerontology. His research interests are in new drug development and in the treatment of gastrointestinal cancers with an emphasis on pancreatic, cholangiocarcinoma, and colon cancers. He also conducts early clinical trials in prostate cancer. He completed a drug development scholarship at the Virginia G Piper Cancer Center Clinical Trials/HonorHealth Research Institute in Scottsdale where he served as the principal investigator and sub-investigator in many early clinical trials in solid tumors. He also has an interest both in developing new biomarkers and targeted therapies in pancreatic cancer.
He earned his M.D. with High Honors from Univerzita Komenskeho (Slovak Republic), and completed a residency in Internal Medicine and a fellowship in Geriatrics and Gerontology at Weill Cornell Medical College, New York Presbyterian Hospital (Queens and New York). Dr Babiker was an instructor in medicine at the Mayo Clinic College of Medicine in Phoenix. He also completed a Hematology and Medical Oncology fellowship at the University of Arizona where he also served as Chief Fellow. Dr Babiker is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the American College of Physicians. He has authored several abstracts and peer review manuscripts and has a passion for teaching and mentoring students and trainees.
- Medical Oncology
- Drug Development
- Geriatrics and Gerontology
- Internal Medicine
- Drug development
- Pancreatic cancer
- GI malignancies
- Prostate cancer-early clinical trials
Chang J, Babiker HM, Serynek S, et al. Compliance With The Joint National Committee VII Guidelines And Effectiveness In The Management Of Hypertension In An Outpatient Community Care Clinic At A Teaching Institution. Resident Research Journal NYHQ 2007.
Babiker HM, Stiefeld R, Vikram HR. Granulomatous Cholangitis As A Complication Of Intravesical BCG Administration for Bladder Cancer. BJU International.10/2011 .
Borad MJ, Curtis KK, Babiker HM, et al. The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer. 2012;3:345-53.
Babiker HM, Wiedenbeck T, Robetorye RS, et al. Acute systemic viral infection masquerading as an infiltrating lymphoma in an elderly patient: a case report and review of the literature.Case Rep Med. 2013: 318358.
Rogowitz E, Babiker HM, Krishnadasan R, et al. Heart of Lymphoma: Primary Mediastinal Large B-Cell Lymphoma with Endomyocardial Involvement.Case Rep Oncol Med.2013:814291.
Yu Q, Babiker HM, Green M,et al. A Conundrum Of A Case: Hemophagocytic Lymphohistiocytosis In An Adult Patient. Poster session presented at: ACP Arizona Chapter 2013 Annual Scientific Meeting; 2013 Nov 15-17;Tucson, AZ.
Babiker HM, Kovoor A, Green MR, et al. Phase I study of concomitant pemetrexed and cisplatin plus radiation in patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinomas. J Clin Oncol (Meeting Abstracts) January 2014 vol. 32 no.3 suppl 145.
Brown GE, Babiker HM, Cantu CL, et al.“Almost Bleeding to Death”: The Conundrum of Acquired Amegakaryocytic Thrombocytopenia. Case Rep Hematol.2014:806541.
Rogowitz E, Babiker HM, Kannan M, et al. Neuroblastoma of the elderly, an Oncologist’s Nightmare: case presentation, literature review and SEER database analysis. Exp Hematol Oncol. 2014 Jul 17;3:20.
Patel S, Maher K, Babiker H. A rare case of tracheal cancer presenting as epistaxis. A J Respir Crit Care Med 189: 2014; A 2926.
Kanaan M, Kovoor A, Babiker HM, et al. A Surveillance Epidemiology and End Results (SEER) database review of epidemiology and outcome of ampullary cancer compared to cholangiocarcinoma.J Clin Oncol 32, 2014 (suppl; abstract e15147).
Babiker HM, Proytcheva M. Basophilic blast phase of chronic myelogenous leukemia.Blood 2014 Oct 124(15):2464.
Taverna JA, Babiker HM, Yun S., Bishop MC, Lau-Braunhut S, Meyer PN, Enzler T. The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res. 2014 Dec 2(1):23.
Borad MJ, Babiker HM, Anthony S, et al. A Multicenter, Open-Label, Phase 1 Study Evaluating The Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma.Cancer Invest. 2015 May 33(5):172-9.
Babiker HM, Green MR, Nelson MA, Elquza E. Oxaliplatin-induced neuropathy: a tale of two electrolytes. Support Care Cancer 2015 June 23(6):1483-5.
Ong SY,Taverna JA, Jokerst C, Babiker H, et al. Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix. Case Reports in Oncological Medicine, vol. 2015, Article ID 212543, doi:10.1155.
Howell KJ, Babiker H, Kovoor A, Green M, Dragovich T, Elquza, E., ... & Hazard L. Phase I Study of Concomitant Pemetrexed and Cisplatin Plus Radiation in Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinomas: Updated Results. International Journal of Radiation Oncology* Biology* Physics, 93(3), E126.
Elquza E, Babiker HM, Howell KJ, et al.Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas.Cancer Invest. 2016 Jan 25:1-7.
Aguiar P Jr, De Mello R, Tadokoro H, Gutierres B, Barreto C, Babiker H, Lopes G. An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil: Track: Immunotherapy. J Thorac Oncol. 2016 Oct;11(10S):S246. doi: 10.1016 PMID: 27676579
Aguiar P Jr, De Mello R, Tadokoro H, Santoro I, Babiker H, Avancha K, Gutierres B, Barreto C, Lopes G. O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. J Thorac Oncol. 2016 Oct;11(10S):S169-S170. doi: 10.1016 PMID: 27676474
Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic Virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother. 2017 Feb 9;6:11-18. doi: 10.2147/OV.S100072 PMID:; 28224120
Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. Anticancer Drugs. 2017 Feb;28(2):127-132. doi: 10.1097 PMID: 27685167
Translational Genomics Rsearch Institute, VGPCC Clinical Trials, and SouthWest Oncology Group (SWOG).
- Graduated with High Honors, Univerzita Komenskeho
- State Health Registry of Iowa (Cancer) and SEER Certification of Appreciation
- Mayo Clinic College of Medicine, Mayo Clinic, Department of Medicine, Phoenix, AZ, Instructor in Medicine
- Chief Fellow, Division of Hematology & Oncology, University of Arizona
- Millennium Scientific and Professional Development Grant Awardee
- Honor-Health Research Institute Investigator Grant
- Drug Development Scholar, Virginia G Piper Cancer Center Clinical Trials/HonorHelath Research Institute & TGen
- University of Arizona, Department of Medicine – Assistant Professor of Medicine, Associate Director of Phase I Program. Division of Hematology & Oncology
- University of Arizona Cancer Center – Research Member
- Drug Development Scholar, Virginia G Piper Cancer Center Clinical
- Clinical Trials/HonorHealth Research Institute & TGen
- University of Arizona, Hematology and Oncology
- Weill Cornell Medical College, New York Presbyterian Hospital
- American Society of Clinical Oncology
- American Association of Cancer Research
- American Society of Hematology
- American College of Physicians
- Mayo Clinical Alumni Association
- Southwest Oncology Group
- Weill Cornell Medical Center Alumni Council
- Medical Oncology
- Geriatrics & Gerontology
- Internal Medicine